Clinical Trial

Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal Melanoma

Terminated Phase 2
View on ClinicalTrials.gov →
Why the trial stopped
PI opted to close study due to poor accrual.
Summary
The purpose of this study is to evaluate the efficacy of lenvatinib and pembrolizumab to treat metastatic uveal melanoma.
Protocol Amendment History 3 changes
critical Trial terminated 2026-08-13
critical Trial terminated: PI opted to close study due to poor accrual. 2026-08-13
minor Completion moved earlier: 2027-06 -> 2025-08-11 2026-08-13
Trial Details
NCT Number NCT05308901
Lead Sponsor Providence Health & Services
Collaborators: Merck Sharp & Dohme LLC, Eisai Inc.
Conditions Melanoma, Uveal
Enrollment 6 participants
Start Date 2022-08-02
Primary Completion 2024-12-03 (estimated)
Study Completion 2025-08-11 (estimated)
Updated on ClinicalTrials.gov 2026-08-12